Percutaneous transluminal coronary angioplasty in a patient with paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired chronic hemolytic anemia associated with an unusual susceptibility to hemolytic crisis, infection, and venous thrombosis which would be aggravated by a number of factors including surgery. We report a case of PNH undergoing percutaneous transluminal coronary angioplasty and discuss the corresponding perioperative management.     

99Tcm and 111In leucocyte scintigraphy in inflammatory bowel disease.

A comparative study of 99Tcm-hexamethylpropyleneamine oxime (HMPAO) and 111In leucocyte scintigraphy was performed in inflammatory bowel disease. Two hundred and thirty-four patients were studied, 146 had 99Tcm-HMPAO, 82 had 111In and six had both. The sensitivity, specificity and accuracy of the 99Tcm leucocyte scan were 96, 97 and 97%, respectively, and 96, 97 and 97%, respectively, for the 111In leucocyte scan. 99Tcm-HMPAO leucocytes demonstrated similar diagnostic accuracy to 111In-labelled leucocytes with improved image quality and reduced radiation dose.     

急性重复性缺氧小鼠脑组织中儿茶酚胺类神经递质含量变化的研究

用高效液相-电化学检测器测定急性重复性缺氧小鼠脑组织中DOPA、DA、NE和Ep等儿茶酚胺类物质的含量。结果发现:与空白对照组(A组)比较,缺氧1次的实验对照组(B组)及急性重复缺氧4次实验组(C组),随缺氧次数增加,小鼠脑组织中的DA含量显着上升(P<0.01),NE、DOPA含量明显降低(P<0.05或<0.01);A组与急性重复4次缺氧后饲养2d的实验对照组(D组)小鼠脑组织中儿茶酚胺类含量接近,没有统计学意义(P=23.77).结果提示脑组织中儿茶酚胺类物质可能参与急性重复缺氧小鼠的耐缺氧能力的形成,而且是一个可逆的快反应。     

Effect of Salvia miltiorrhiza on the left ventricular diastolic function in coronary artery stenosis

In 24 open-chest mongrel dogs, coronary artery critical stenosis were produced by a micrometer constriction on left circumflex coronary artery. It was reduction about 87% in lumen area. CBF, -Vce, -dp/dt max were decreased, T was increased (P less than 0.01). 15 minutes after stenosis, the Salvia miltiorrhiza injection was injected into left atrium. CBF, -dp/dt max, -Vce were increased and T was decreased after the injection of Salvia miltiorrhiza. Moreover, the change of CBF was the earliest. The results proved that the Salvia miltiorrhiza could improve the left ventricular diastolic function in coronary artery stenosis.     

依那普利治疗高血压病的临床观察

本文报告应用新的转换酶抑制剂依那普利(enalapril)治疗59例原发性高血压的临床疗效。采甩随机单盲及双盲法进行,对照药为巯甲丙脯酸。结果表明:依那普利使收缩压及舒张压均降低10％以上(由21.5±1.6/13.8±0.9kPa降至19.2±2.2/12.3±1.0kPa),总有效率为74.2％,与巯甲丙脯酸相仿,但前者作用持续时间显著延长。半数患者的有效剂量为10mg/d,80％在20mg/d以下。本药对血像、肝肾功能、血电解质及糖、脂类代谢未见明显影响。     

中药混乱品种鉴别研究——7. 蕲蛇及其混淆品鉴别之二

作者前已报道蕲蛇及其伪品滑鼠蛇的鉴别,又据报道有些省发现蕲蛇商品药材中混有烙铁头、山烙铁头两种蛇的干燥体。作者对这两种混淆品与蕲蛇在体表花纹、鳞片以及骨骼的形态与组织特征等方面进行了鉴别研究。     

乙型肝炎甲胎蛋白检测与重型肝炎预后指数评估的意义

给慢性活动肝炎患者输注人胎肝细胞悬液引起血清甲胎蛋白增高反应的初浓度为２０２±３８．３μｇ／Ｌ，其半衰期为１．７天；分布池为６．９一１０．２升。重型肝炎生存组血清甲胎蛋白显著高于死亡组，生存组甲胎蛋白与血清总胆红素呈非常显著相关，而死亡组两者无相关性。重型肝炎患者输注胎肝悬液后其血清甲胎蛋白进一步升高者，预后较好。取重型肝炎预后指数０．１为重型肝炎生死的截断点，判断预后的灵敏度、特异度、准确度和阳性预告值分别为７９．５％、８９．６％、８４．８％和８７．５％。重型肝炎预后指数的计算可作为判断预后与新疗法疗效的指标。     

大黄对实验性糖尿病大鼠肾脏肥大及高滤过作用的影响

肾脏肥大和高滤过是糖尿病肾病出现最早的病理生理特征。本研究利用中药大黄抑制糖尿病的肾脏肥大,试图达到控制其高滤过现象。实验结果表明,大黄能明显地抑制糖尿病肾脏肥大及其组织中蛋白质、DNA含量的增加;大黄治疗组的菊粉清除率明显低于非治疗组;此外,大黄还能使糖尿病血清甘油三酯、胆固醇水平降低。结论:大黄可以通过影响糖尿病肾病肾脏肥大,降低高滤过和纠正血脂代谢紊乱,治疗实验性糖尿病肾病动物模型。     

念珠状链杆菌在小鼠群中的自然感染和发病特征的观察

本文在国内首次报告了念珠状链杆菌在清洁级Ｃ５７ＢＬ／６Ｊ小鼠群中的自然感染，并从临床、病理解剖、病原学及流行病学方面进行了较为详细的观察，在受检的１４例发病动物中，颈部淋巴结肿大、化脓占７１．４％，皮下、肺门淋巴结脓肿分别占５０．０％和２１．４％，多发性关节炎（包括趾、跗关节）占２１．４％，子宫积脓占７．１％，从所有病灶及部分动物的血液、脾、肝、肺、肾均分离到了单一的细菌。该菌在小鼠成功地进行了急性感染实验，受感染动物出现了典型的念珠状链杆菌病的临床及病理特征，即败血症、关节炎、淤血、水肿、紫绀、结膜炎等。所分离的致病菌在病原学上也完全符合念珠状链杆菌的病原学特征。在饲养环境上与发病鼠群有密切关系的其它４个品系小鼠群，即６１５、ＢＡＬＢ／ｃ、ＣＢＡ、ＫＭ，均未波感染，证明在对该菌的易感性方面存在品系差异。     

LONG-TERM OUABAIN ADMINISTRATION DOES NOT ALTER BLOOD PRESSURE IN CONSCIOUS SPRAGUE-DAWLEY RATS

1. We tested the ability of ouabain to cause chronic hyper tension by continuously infusing ouabain for 28 days (mini-osmotic pump implantation; i.p.). The blood pressure and metabolic effects of sham (150 mmol/L NaCI; n= 12) or ouabain infusion (10 μg/kg per day; n= 14; 100 μg/kg per day; n = 14) were examined in conscious Sprague-Dawley rats. 2. Plasma ouabain concentrations measured after 28 days of ouabain infusion were as follows: sham, not detectable (n= 11); ouabain 10 μg/kg per day, 0.60 ± 0.07 nmol/L (n= 14); and ouabain 100 μg/kg per day, 7.17 ± 0.57 nmol/L (n= 14; P < 0.001). 3. Sham or ouabain infusion did not alter food intake, bodyweight, water intake or urine output in conscious rats. 4. Blood pressure was not altered by sham treatment. Ouabain at 10 μg/kg per day or 100 μg/kg per day did not produce consistent rises in blood pressure. Ouabain at 10 μg/kg per day increased blood pressure on treatment day 12 only (+ 6mmHg; P < 0.05), while at 100μg/kg per day blood pres sure increased on treatment days 16 (+ 9 mmHg; P < 0.05) and day 18 (+ 8mmHg; P < 0.05) only. There was no significant difference in blood pressure between sham and ouabain groups. 5. Renal blood flow was decreased in rats infused with ouabain at 10 μg/kg per day (2.0 ± 0.3 mL/min per 100 g body-weight; n= 5; P < 0.01) and 100 μg/kg per day (2.2 ± 0.4 mL/ min per 100 g bodyweight; n= 7; P < 0.05) compared with sham treatment (3.5 ± 0.2 mL/min per 100 g bodyweight; n= 6). Renal vascular resistance was increased in rats treated with ouabain at 10 μg/kg per day (65.5 ± 12.6 mmHg/mL per min per 100 g bodyweight; n= 5; P < 0.01) and 100 μg/kg per day (66.0 ± 15.6 mmHg/mL per min per 100 g bodyweight; n= 7; P < 0.05) compared with sham treatment (32.6 ± 2.5 mmHg/mL per min per 100 g bodyweight; n= 6). 6. High plasma concentrations of ouabain do not cause consistent increases in blood pressure in conscious Sprague-Dawley rats.